Centers for Disease Control and Prevention researchers this week at the 12th Conference on Retroviruses and Opportunistic Infections in Denver reported that injections of two drugs used to treat HIV patients completely protected monkeys from becoming infected.
The rhesus monkeys were injected with a version of Truvada, Gilead Science's once-daily pill that includes its drugs Viread and Emtriva. The monkeys were then exposed rectally to combined monkey-human HIV. The exposures and the injections continued daily for 14 days. "Treatment continued for four weeks after last challenge," says Walid Heneine of CDC.
The six monkeys that received the drug injections were all completely protected from infection. Nine monkeys used in a previous experiment eventually all became infected.
In a statement, the CDC says, "Study authors believe the findings may be the strongest animal data yet suggesting that potent antiretrovirals given before HIV exposure may prevent sexual HIV transmission." However, they caution that the drug dose differed slightly from that found in people taking Truvada. Studies that could determine whether the findings will translate to humans are ongoing. (Reuters)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.